- Home
- TSLX vs NVCR Comparison
TSLX vs NVCR Comparison
Compare TSLX & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSLX
- NVCR
- Stock Information
- Founded
- TSLX 2010
- NVCR 2000
- Country
- TSLX United States
- NVCR Switzerland
- Employees
- TSLX N/A
- NVCR N/A
- Industry
- TSLX Investment Managers
- NVCR Medical/Dental Instruments
- Sector
- TSLX Finance
- NVCR Health Care
- Exchange
- TSLX Nasdaq
- NVCR Nasdaq
- Market Cap
- TSLX 2.1B
- NVCR 1.9B
- IPO Year
- TSLX 2014
- NVCR 2015
- Fundamental
- Price
- TSLX $23.83
- NVCR $17.92
- Analyst Decision
- TSLX Strong Buy
- NVCR Buy
- Analyst Count
- TSLX 8
- NVCR 6
- Target Price
- TSLX $22.69
- NVCR $32.83
- AVG Volume (30 Days)
- TSLX 558.0K
- NVCR 1.8M
- Earning Date
- TSLX 07-30-2025
- NVCR 07-24-2025
- Dividend Yield
- TSLX 8.74%
- NVCR N/A
- EPS Growth
- TSLX N/A
- NVCR N/A
- EPS
- TSLX 1.89
- NVCR N/A
- Revenue
- TSLX $481,092,000.00
- NVCR $621,711,000.00
- Revenue This Year
- TSLX N/A
- NVCR $5.56
- Revenue Next Year
- TSLX N/A
- NVCR $9.19
- P/E Ratio
- TSLX $12.60
- NVCR N/A
- Revenue Growth
- TSLX 4.73
- NVCR 18.27
- 52 Week Low
- TSLX $18.58
- NVCR $14.17
- 52 Week High
- TSLX $23.98
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- TSLX 63.19
- NVCR 52.99
- Support Level
- TSLX $22.76
- NVCR $16.19
- Resistance Level
- TSLX $23.98
- NVCR $18.70
- Average True Range (ATR)
- TSLX 0.35
- NVCR 0.77
- MACD
- TSLX 0.01
- NVCR 0.09
- Stochastic Oscillator
- TSLX 85.54
- NVCR 67.53
About TSLX Sixth Street Specialty Lending Inc.
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.